There are currently 1877 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Genetic Testing in Young Adults With Cancer Study
NCT04533555
Recruiting
The overarching goal of our research is to define an evidence-based, sustainable approach to identifying and managing genetic risk among young adults with cancer and their relatives. Conventional practice leaves referral and testing decisions to mostly non-expert clinicians implementing complex guidelines at the point of care, leading to substantial under-utilization. The investigators hypothesize that panel-based universal screening coupled with electronic medical record- (EMR-) based algorithm... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
02/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Localizing Epileptic Networks Using MRI and iEEG
NCT04649008
Recruiting
Upon successful completion of this study, the investigators expect the study's contribution to be the development of noninvasive imaging biomarkers to predict IEEG functional dynamics and epilepsy surgical outcomes. Findings from the present study may inform current and new therapies to map and alter seizure spread, and pave the way for less invasive, better- targeted, patient-specific interventions with improved surgical outcomes. This research is relevant to public health because over 20 milli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
Register for Updates
Different Doses of Naronapride Vs. Placebo in Gastroparesis
NCT05621811
Recruiting
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/04/2025
Locations: Dr Falk Investigational Site, Philadelphia, Pennsylvania
Conditions: Gastroparesis
Register for Updates
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
NCT05622721
Recruiting
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly. Drawing on observations that pet ownership and close contact with pets are protective against colonization with C. difficile and recurrence of C. difficile infection, the proposed study will test the hypothesis that microbiota that provide colonization resistance against C. difficile are shared betw... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: The Robert Schattner Center, University of Pennsylvania, School of Dental Medicine, Philadelphia, Pennsylvania
Conditions: Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
Register for Updates
Reducing Patient Memory Recall in the Burning Mouth Patient Population
NCT05819697
Recruiting
The goal of this study is to learn about burning mouth syndrome symptoms in real time in patients with burning mouth syndrome. The main questions it aims to answer are: (1) To test the ability of a smartphone app to collect repeated observations of individual data to assess fluctuations in BMS symptoms (pain) at multiple points in the day as they happen; (2) To evaluate a panel of salivary biomarkers in patients with burning mouth syndrome (BMS) and to study their relationship with clinical var... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Burning Mouth Syndrome
Register for Updates
BSGM to Evaluate Patients With GI Symptoms
NCT05880199
Recruiting
The goal of this observational study is to learn about gastric myoelectric activity in children with GI symptoms. The main question it aims to answer is which patterns or signals are associated with GI symptoms as measured by a body surface gastric mapping (BSGM) device. Participants will have their stomach activity recorded for up to 4 hours using the BSGM device and log real-time symptoms. Researchers will compare the recordings of healthy children and children with GI symptoms to define abnor... Read More
Gender:
ALL
Ages:
Between 8 years and 25 years
Trial Updated:
02/04/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Gastrointestinal Motility Disorders in Children, Functional Gastrointestinal Disorders, Gastroparesis, Dyspepsia and Other Specified Disorders of Function of Stomach
Register for Updates
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
NCT02356653
Recruiting
The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
02/03/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes, Immunodeficiencies, Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Register for Updates
Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children
NCT03419260
Recruiting
Electrographic seizures are common in critically ill patients leading to increased use of resource-intense continuous EEG monitoring for seizure identification and management. When identified, electrographic seizures are generally treated with anti-seizure medications, but there are very limited data available regarding optimal treatment in terms of the efficacy or safety of specific anti-seizure medications or overall management strategies. This is a single-center prospective observational stu... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
02/03/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Seizures
Register for Updates
BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826
Recruiting
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023
Recruiting
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Frontotemporal Dementia
Register for Updates
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 114, Philadelphia, Pennsylvania
Conditions: Chronic Spontaneous Urticaria
Register for Updates